CA2169735A1 - Oral compositions of h2-antagonists - Google Patents
Oral compositions of h2-antagonistsInfo
- Publication number
- CA2169735A1 CA2169735A1 CA 2169735 CA2169735A CA2169735A1 CA 2169735 A1 CA2169735 A1 CA 2169735A1 CA 2169735 CA2169735 CA 2169735 CA 2169735 A CA2169735 A CA 2169735A CA 2169735 A1 CA2169735 A1 CA 2169735A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- calcium carbonate
- antagonist
- weight
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Chewable tablets of H2-antagonists which are tasteless in the mouth, but give good release of active ingredients are prepared using calcium carbonate and a supportive aluminum silicate. Also contributing to the formulation are such non-essentials as xylitol and fruit acids.
Description
2 ~ 6 9 7 3 ~ PCTIUS94/09204 Description This invention relates to pharmaceutically elegant compositions of therapeutic compounds having H2-antagonist activity especially adapted for convenient oral administration.
Background of the Invention Magnesium aluminum silicates have been known in the pharmaceutical art to be useful to mask the bitter taste of a variety of medicinal agents. U.S. Patent No.
Background of the Invention Magnesium aluminum silicates have been known in the pharmaceutical art to be useful to mask the bitter taste of a variety of medicinal agents. U.S. Patent No.
3,140,978 (M. R. Zentner), together with related patents such as 3,248,290, 3,337,402, 3,337,403, as well as U.S.
Patent No. 4,711,774 (J. Denick Jr.), together with 4,716,033, 4,717,565, 4,758,424, 4,758,425 and 4,761,274, describe the adsorption of medications of many therapeutic classes onto magnesium aluminum silicates as well as the suspensions, granulations, lozenges, chewable tablets and the like prepared from the resulting complexes using standard formulation methods. None of these mention the use of H2-antagonists as the active therapeutic agent.
Other specific applications of magnesium alllm;nl~m silicates to formulation procedures are disclosed in U.S.
Patent Nos. 3,432,593 (M. Shepard), 3,567,819 and 4,753,800. These also are of a specific aim and are believed cumulative as well to the two basic references of Zentner and Denick mentioned above.
U.S. Patent No. 4,719,228 (D. Rawlins) discloses the use of selected synthetic silicas to form free flowing powder products of a number of therapeutic classes of drugs including antiulcer drugs. No reference to H2-antagonists is made here.
The scientific literature contains studies of the use of silicate clays in formulating various drugs of different chemical types and the nature of the binding forces involved. In general, the release of the active ingredient from such formulations is uncertain but is 2i~9~ 3~
often retarded by clay admixture, J.W. McGinity et al., J.
Pharm. Sc. 65, 896; J.T. Carstensen et al., J. Pharm. Sc.
60 733. Certain electrolytes such as sodium and magnesium chloride are reported to facilitate the release of antibiotics from clay adsorbates, J.W. McGinity et al., J.
Pharm. Sc. 64, 1567.
An effervescent tablet containing ranitidine as the active H2-antagonist agent has been reported. This pharmaceutical form, which contains sodium acid pyrophosphate, an acid salt, demonstrated substantial reduced bioavailability of the active ingredient (54%).
K.M. Koch et al., Pharm. Res. 10 1027 (1993).
U.S. Patent No. 5,219,563 (S.J. Douglas) reports adsorbates of ranitidine on synthetic ion exchange resin.
Disclosure of the Invention This invention relates to pharmaceutical oral compositions cont~;n;ng one or more H2-antagonist drugs.
These compositions do not exhibit a bitter taste in the mouth and distribute the active ingredient substantially in the gastrointestinal tract. The composition contains, as essential ingredients, an H2-antagonist - magnesium aluminum silicate complex and calcium carbonate. The dosage unit form is any which would normally expose the bitter H2-antagonist to the taste of the patient but is preferably a chewable tablet. For larger doses, it may be a sachet, lozenge or packaged flavored granules.
Best Mode for Carrying Out the Invention Most drugs which have H2-antagonist activity, and are thereby useful for treating various gastrointestinal disorders such as ulcers, dyspepsia or gastrointestinal reflux indications, have a bitter taste. The H2-compounds are preferably administered orally. For the usual prescription use, the oral product forms of these compounds are capsules or coated tablets. Certain segments of the patient population prefer more easily ingested product forms. This is most evident in the over-the-counter market. One of the most useful of such 21 ~9 73~
WO95/05l73 PCT~Sg4/09204 _3_ ~. :
product forms is the chewable or frangible tablet, lozenge or troche. Examples of the preparation of chewable products are found in U.S. Patent No. 4,711,774 which is cited in the Background section above.
As stated above, the pharmaceutical art has long recognized that the natural or processed magnesium aluminum silicates adsorb a wide variety of medicaments to some degree. Natural clays such as attapulgite and montmorillonite have been used, but, in our hands, these are not as satisfactory for use with H2-antagonists as are the processed silicates known by the trade name "Veegum".
The latter are also described in detail in the above cited prior art and are widely accepted for pharmaceutical use.
The literature describes the nature of silicate-drug binding and the uncertain release of various active ingredients from the adsorbate complex. Mechanical and chemical methods of increasing the reliability of release are many but, more often than not, unsuccessful. Ionic additives such as the halide salts have not been successful due to the side effects due to large ingestions of such salts.
This i~nvention is based on several discoveries which are unique with the u~e of H2-antagonists. Firstly, the H2-antagonist compounds form tasteless adsorbates with magnesium aluminum silicate readily and substantially completely. Secondly, the addition of a selected quantity of calcium carbonate dramatically improves the release of active ingredient from the silicate adsorbate, but does not cause overt side effects such as substantial release of carbon dioxide by effervescence. This is so especially when the formulations are prepared with acid addition salts of the biologically active ingredients or with added solid acid formulation aids such as the fruit acids, for example citric acid, within the granules in the formulation process. The complex between the active biological ingredient and the magnesium aluminum silicate WO95/05173 2 ~ ~ 9 ~ 35 PCT~S94/09204 -is usually formed in situ, that is, during the formulation of the dosage unit composition.
The composition of this invention, therefore, is in its preferred form a chewable tablet comprised essentially of a therapeutically effective but non-toxic dosage unit quantity of an H2-antagonist complex formed with a magnesium aluminum silicate, which complex is usually prepared during formulation, and a quantity of calcium carbonate.
The magnesium aluminum silicate which is the support component of this combination is preferably the commercial product known as "Veegum" supplied by R.T. Vanderbilt Company, Inc. Analysis of the commercial product is carried out as oxide contents. No control of the particle size of the commercial grade of product has been found necessary. Comprehensive descriptions of the product are in the Zentner-Denick patents noted above.
The exact quantity of the silicate support is not critical to the invention as long as enough is present to completely adsorb the drug component in situ. An excess is most convenient and preferred with ranges of from lO -30% by weight of the dosage unit. Magnesium aluminum silicates have been used in the literature to delay the release of other active ingredients in time release products when used in excess. This is in contrast to the present invention which affords good quick release of drug.
The H2-antagonist, in either the base or its acid addition salt form as appropriate, is preferably selected from those approved for use in either the prescription or over-the-counter pharmaceutical markets. The dosage units will contain either a full therapeutic dose or a partial dose for a subject in need of relief so that from 1-5 units may be administered per day to obtain satisfactory treatment of symptoms. The non-prescription products usually contain a lower dose, often about half the quantity. Examples of active H2-antagonists and suggested WO95/05173 21~69 735 PCT~Sg4/09204 doses are cimetidine (300 mg), nizatidine (150 mg), roxatidine (acetate), famotidine (20 mg), ranitidine (150 mg), tiotidine, lamtidine, mifentidine, zaltidine, KV-1257 or loxtidine (Handbook Exp. Pharmacol. 97 573-748 (1991), "Histamine and Histamine Antagonists").
The daily dose range of active ingredient is a nontoxic but H2-antagonist effective quantity and may be chosen from 40 to 1600 mg. The dosage units may range from 10 - 800 mg of active ingredient depending on the known individual activity and market of the H2-antagonist drug. The units are administered from 1-5 times daily orally to a patient in need of H2-antagonist treatment.
The H2-antagonist may be present either as the base if appropriate or as a salt thereof with a nontoxic, pharmaceutically acceptable acid. Usually, the dose and the form which is commercially available is conveniently used. Surprisingly, the H2-antagonist-silicate adsorbate is formed substantially completely during formulation despite which base or salt form of the active H2-antagonist is selected.
Preferably, the calcium carbonate is selected from the range of 75-500 mg per dosage unit.
The calcium carbonate supplemented product is preferably used in non-toxic quantities in up to 5 units per day. A general range of calcium carbonate content of the oral product is from about 1-35% by weight of the chewable tablet products. For example, for a 1500 mg.
tablet as much as 500 mg. of calcium carbonate may be present. Overt evolution of carbon dioxide has not been observed when the compositions contact water. One skilled in the art will recognize that the size of chewable tablets may be larger than that of normal compressed tablets.
A variety of other pharmaceutical additives may be optionally used in the composition of this invention in addition to the essential ingredients described above.
Among these are bulking agents, flavoring agents, WO95/05173 2~9~ 3~ PCT~Sg4/09204 -granulating agents, buffering agents, coloring agents, preservatives, confectioneries and the like. Reference may be made to U.S. Patent No. 4,711,774 for more specific formulation information.
Especially useful optional ingredients are the solid fruit acids such as citric, malic or tartaric acids in up to 3% by weight for good stability and palatability of the chewable tablet as well as xylitol or mannitol as a sweetening-bulking agent in up to 70~ by weight. Citric acid as well as xylitol are particularly advantageous since each contributes unexpectedly well to the palatability of the chewable tablets. When such acids are used for this purpose, quantity of calcium carbonate and acid should be selected to insure good release, but not to cause overt carbon dioxide evolution. The absence of the acid component gives acceptable products as well.
The chewable tablets of this invention are prepared by mixing the H2-antagonist compound with magnesium aluminum silicate in a weight ratio chosen from the range of 1 to 1 down to 1 to 10 with an optional sweetening agent in a mixer, adding water to form the complex and granulate. The dried and milled granules are mixed with the calcium carbonate, bulking-sweetening agents and tabletting aids then compressed into tablets.
The chewable pharmaceutical products are taken by the subject in need of H2-antagonist treatment orally from 1 to 5 times daily as required to satisfy the acceptable daily dosage regimen of active ingredients. It should be particularly noted that the antacid component of the chewable tablet may also contribute to lowering the acid content of the gastrointestinal tract. The dosage units should be prepared and used with this in mind.
The method of analysis used and detailed hereafter is the ultraviolet dissolution method as reported in the USP
XXII (p. 3074). Usually times for pulling samples were 15, 30, 45, 60 minutes. The ultraviolet wave lengths vary, of course, with the active ingredient. Cimetidine WO95/05173 21 ~9 73$ PCT~Sg4/09204 is at 218 nm. Nizatidine and ranitidine are at 314 nm.
Famotidine is at 265 nm.
The following embodiments of this invention are designed to illustrate and teach the specific use of the invention but not to limit its scope.
W 095/05173 2 1~ 9 7 -8- PCTrUS94109204 -Example 1 % By Weight A B C D
Ingredient~ r Nizatidine USP 5 - - -Cimetidine USP - 5 Ranitidine USP - - 5 Famotidine USP - - - 2 Magnesium Aluminum Silicate NF 25 25 25 lO
Sodium Sac~-hA r; n NF .25.25 .25 .125 Mannitol NF Q.S. Q.S.Q.S Q.S.
Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF
Magne~ium Stearate NF l.5 l.5 l.5 l.5 Flavor~ Q.S. Q.S. Q.S. Q.S.
Purified water*
* Remove during proce~ing Method of Manufacturing l. Mix drug with magne~ium al~ 'nnm ~ilicate and ~odium ~aCChAr; n in a planetary mixer for five minute~.
2. Add water until a uniform granulation occur~.
3. Dry the granule~.
4. Size the granule~ into fine powder.
5. Add mannitol, xylitol and colloidal ~ilicon dioxide and mix for ten minutes.
Patent No. 4,711,774 (J. Denick Jr.), together with 4,716,033, 4,717,565, 4,758,424, 4,758,425 and 4,761,274, describe the adsorption of medications of many therapeutic classes onto magnesium aluminum silicates as well as the suspensions, granulations, lozenges, chewable tablets and the like prepared from the resulting complexes using standard formulation methods. None of these mention the use of H2-antagonists as the active therapeutic agent.
Other specific applications of magnesium alllm;nl~m silicates to formulation procedures are disclosed in U.S.
Patent Nos. 3,432,593 (M. Shepard), 3,567,819 and 4,753,800. These also are of a specific aim and are believed cumulative as well to the two basic references of Zentner and Denick mentioned above.
U.S. Patent No. 4,719,228 (D. Rawlins) discloses the use of selected synthetic silicas to form free flowing powder products of a number of therapeutic classes of drugs including antiulcer drugs. No reference to H2-antagonists is made here.
The scientific literature contains studies of the use of silicate clays in formulating various drugs of different chemical types and the nature of the binding forces involved. In general, the release of the active ingredient from such formulations is uncertain but is 2i~9~ 3~
often retarded by clay admixture, J.W. McGinity et al., J.
Pharm. Sc. 65, 896; J.T. Carstensen et al., J. Pharm. Sc.
60 733. Certain electrolytes such as sodium and magnesium chloride are reported to facilitate the release of antibiotics from clay adsorbates, J.W. McGinity et al., J.
Pharm. Sc. 64, 1567.
An effervescent tablet containing ranitidine as the active H2-antagonist agent has been reported. This pharmaceutical form, which contains sodium acid pyrophosphate, an acid salt, demonstrated substantial reduced bioavailability of the active ingredient (54%).
K.M. Koch et al., Pharm. Res. 10 1027 (1993).
U.S. Patent No. 5,219,563 (S.J. Douglas) reports adsorbates of ranitidine on synthetic ion exchange resin.
Disclosure of the Invention This invention relates to pharmaceutical oral compositions cont~;n;ng one or more H2-antagonist drugs.
These compositions do not exhibit a bitter taste in the mouth and distribute the active ingredient substantially in the gastrointestinal tract. The composition contains, as essential ingredients, an H2-antagonist - magnesium aluminum silicate complex and calcium carbonate. The dosage unit form is any which would normally expose the bitter H2-antagonist to the taste of the patient but is preferably a chewable tablet. For larger doses, it may be a sachet, lozenge or packaged flavored granules.
Best Mode for Carrying Out the Invention Most drugs which have H2-antagonist activity, and are thereby useful for treating various gastrointestinal disorders such as ulcers, dyspepsia or gastrointestinal reflux indications, have a bitter taste. The H2-compounds are preferably administered orally. For the usual prescription use, the oral product forms of these compounds are capsules or coated tablets. Certain segments of the patient population prefer more easily ingested product forms. This is most evident in the over-the-counter market. One of the most useful of such 21 ~9 73~
WO95/05l73 PCT~Sg4/09204 _3_ ~. :
product forms is the chewable or frangible tablet, lozenge or troche. Examples of the preparation of chewable products are found in U.S. Patent No. 4,711,774 which is cited in the Background section above.
As stated above, the pharmaceutical art has long recognized that the natural or processed magnesium aluminum silicates adsorb a wide variety of medicaments to some degree. Natural clays such as attapulgite and montmorillonite have been used, but, in our hands, these are not as satisfactory for use with H2-antagonists as are the processed silicates known by the trade name "Veegum".
The latter are also described in detail in the above cited prior art and are widely accepted for pharmaceutical use.
The literature describes the nature of silicate-drug binding and the uncertain release of various active ingredients from the adsorbate complex. Mechanical and chemical methods of increasing the reliability of release are many but, more often than not, unsuccessful. Ionic additives such as the halide salts have not been successful due to the side effects due to large ingestions of such salts.
This i~nvention is based on several discoveries which are unique with the u~e of H2-antagonists. Firstly, the H2-antagonist compounds form tasteless adsorbates with magnesium aluminum silicate readily and substantially completely. Secondly, the addition of a selected quantity of calcium carbonate dramatically improves the release of active ingredient from the silicate adsorbate, but does not cause overt side effects such as substantial release of carbon dioxide by effervescence. This is so especially when the formulations are prepared with acid addition salts of the biologically active ingredients or with added solid acid formulation aids such as the fruit acids, for example citric acid, within the granules in the formulation process. The complex between the active biological ingredient and the magnesium aluminum silicate WO95/05173 2 ~ ~ 9 ~ 35 PCT~S94/09204 -is usually formed in situ, that is, during the formulation of the dosage unit composition.
The composition of this invention, therefore, is in its preferred form a chewable tablet comprised essentially of a therapeutically effective but non-toxic dosage unit quantity of an H2-antagonist complex formed with a magnesium aluminum silicate, which complex is usually prepared during formulation, and a quantity of calcium carbonate.
The magnesium aluminum silicate which is the support component of this combination is preferably the commercial product known as "Veegum" supplied by R.T. Vanderbilt Company, Inc. Analysis of the commercial product is carried out as oxide contents. No control of the particle size of the commercial grade of product has been found necessary. Comprehensive descriptions of the product are in the Zentner-Denick patents noted above.
The exact quantity of the silicate support is not critical to the invention as long as enough is present to completely adsorb the drug component in situ. An excess is most convenient and preferred with ranges of from lO -30% by weight of the dosage unit. Magnesium aluminum silicates have been used in the literature to delay the release of other active ingredients in time release products when used in excess. This is in contrast to the present invention which affords good quick release of drug.
The H2-antagonist, in either the base or its acid addition salt form as appropriate, is preferably selected from those approved for use in either the prescription or over-the-counter pharmaceutical markets. The dosage units will contain either a full therapeutic dose or a partial dose for a subject in need of relief so that from 1-5 units may be administered per day to obtain satisfactory treatment of symptoms. The non-prescription products usually contain a lower dose, often about half the quantity. Examples of active H2-antagonists and suggested WO95/05173 21~69 735 PCT~Sg4/09204 doses are cimetidine (300 mg), nizatidine (150 mg), roxatidine (acetate), famotidine (20 mg), ranitidine (150 mg), tiotidine, lamtidine, mifentidine, zaltidine, KV-1257 or loxtidine (Handbook Exp. Pharmacol. 97 573-748 (1991), "Histamine and Histamine Antagonists").
The daily dose range of active ingredient is a nontoxic but H2-antagonist effective quantity and may be chosen from 40 to 1600 mg. The dosage units may range from 10 - 800 mg of active ingredient depending on the known individual activity and market of the H2-antagonist drug. The units are administered from 1-5 times daily orally to a patient in need of H2-antagonist treatment.
The H2-antagonist may be present either as the base if appropriate or as a salt thereof with a nontoxic, pharmaceutically acceptable acid. Usually, the dose and the form which is commercially available is conveniently used. Surprisingly, the H2-antagonist-silicate adsorbate is formed substantially completely during formulation despite which base or salt form of the active H2-antagonist is selected.
Preferably, the calcium carbonate is selected from the range of 75-500 mg per dosage unit.
The calcium carbonate supplemented product is preferably used in non-toxic quantities in up to 5 units per day. A general range of calcium carbonate content of the oral product is from about 1-35% by weight of the chewable tablet products. For example, for a 1500 mg.
tablet as much as 500 mg. of calcium carbonate may be present. Overt evolution of carbon dioxide has not been observed when the compositions contact water. One skilled in the art will recognize that the size of chewable tablets may be larger than that of normal compressed tablets.
A variety of other pharmaceutical additives may be optionally used in the composition of this invention in addition to the essential ingredients described above.
Among these are bulking agents, flavoring agents, WO95/05173 2~9~ 3~ PCT~Sg4/09204 -granulating agents, buffering agents, coloring agents, preservatives, confectioneries and the like. Reference may be made to U.S. Patent No. 4,711,774 for more specific formulation information.
Especially useful optional ingredients are the solid fruit acids such as citric, malic or tartaric acids in up to 3% by weight for good stability and palatability of the chewable tablet as well as xylitol or mannitol as a sweetening-bulking agent in up to 70~ by weight. Citric acid as well as xylitol are particularly advantageous since each contributes unexpectedly well to the palatability of the chewable tablets. When such acids are used for this purpose, quantity of calcium carbonate and acid should be selected to insure good release, but not to cause overt carbon dioxide evolution. The absence of the acid component gives acceptable products as well.
The chewable tablets of this invention are prepared by mixing the H2-antagonist compound with magnesium aluminum silicate in a weight ratio chosen from the range of 1 to 1 down to 1 to 10 with an optional sweetening agent in a mixer, adding water to form the complex and granulate. The dried and milled granules are mixed with the calcium carbonate, bulking-sweetening agents and tabletting aids then compressed into tablets.
The chewable pharmaceutical products are taken by the subject in need of H2-antagonist treatment orally from 1 to 5 times daily as required to satisfy the acceptable daily dosage regimen of active ingredients. It should be particularly noted that the antacid component of the chewable tablet may also contribute to lowering the acid content of the gastrointestinal tract. The dosage units should be prepared and used with this in mind.
The method of analysis used and detailed hereafter is the ultraviolet dissolution method as reported in the USP
XXII (p. 3074). Usually times for pulling samples were 15, 30, 45, 60 minutes. The ultraviolet wave lengths vary, of course, with the active ingredient. Cimetidine WO95/05173 21 ~9 73$ PCT~Sg4/09204 is at 218 nm. Nizatidine and ranitidine are at 314 nm.
Famotidine is at 265 nm.
The following embodiments of this invention are designed to illustrate and teach the specific use of the invention but not to limit its scope.
W 095/05173 2 1~ 9 7 -8- PCTrUS94109204 -Example 1 % By Weight A B C D
Ingredient~ r Nizatidine USP 5 - - -Cimetidine USP - 5 Ranitidine USP - - 5 Famotidine USP - - - 2 Magnesium Aluminum Silicate NF 25 25 25 lO
Sodium Sac~-hA r; n NF .25.25 .25 .125 Mannitol NF Q.S. Q.S.Q.S Q.S.
Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF
Magne~ium Stearate NF l.5 l.5 l.5 l.5 Flavor~ Q.S. Q.S. Q.S. Q.S.
Purified water*
* Remove during proce~ing Method of Manufacturing l. Mix drug with magne~ium al~ 'nnm ~ilicate and ~odium ~aCChAr; n in a planetary mixer for five minute~.
2. Add water until a uniform granulation occur~.
3. Dry the granule~.
4. Size the granule~ into fine powder.
5. Add mannitol, xylitol and colloidal ~ilicon dioxide and mix for ten minutes.
6. Add magne~ium ~tearate and mix for five minute~.
7. Com~re~ into chewable tablet~.
W 095/OSl73 16~ ~35 PCTrUS94/09204 Example 2 % By Weight A B C D
Ingredient~
Nizatidine USP 5 - - -Cimetidine USP - 5 Ranitidine USP - - 5 Famotidine USP - - - 2 Magne~ium Aluminum Silicate NF 25 25 25 10 Calcium Carbonate 5 5 5 5 Sodium Saccharin NF .25 .25 .25 .125 Mannitol NF Q.S. Q.S. Q.S. Q.S.
Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF
Magne~ium Stearate NF 1.5 1.5 1.5 1.5 Flavorq Q.S. Q.S. Q.S. Q.S.
Purified water~
* Remove during proce-~ing Method of Manufacturing 1. Mix drug with magneqium all nllm ~ilicate and qodium qaccharin in a planetary mixer for five minute~.
2. Add water until a uniform granulation occur~.
3. Dry the granule~.
4. Size the granule~ into fine powder.
5. Add mannitol,.xylitol, calcium carbonate, colloidal ~olicon dioxide to and mix for ten minutes.
6. Add magne~ium -qtearate and mix for five minute~.
7. Compre~ into chewable tablet~.
W 095/05173 ~69 PCTrUS~ 204 ~
If the operator wi~he~ an acid agent ~uch a~ a fruit acid, for example, citric, malic or tartaric acid in the formulation, thi~ i~
added to the -n~f~cturing proce~ at Step 1 before the granulation procesR, u~ually at about 1.5%.
The following comparative examples were ~elected to illu~trate the enhanced relea~e of active ingredient from the granule-~/tablet~ of this invention uYing the preparative and te~ting procedure-Q de~cribed above.
Example 3 The percentage of cimetidine di~301ved in water using the U.S.P.
method II at 50 RPM to 60 minute~ from granule~ with added citric acid (3~), calcium carbonate (75 mg) and without calcium carbonate.
Time Without CaCO3 With CaCO3 39.967.5 44.674.4 46.978.8 48.382.8 51.6104.3 Example 4 Ranitidine Hydrochloride (75 mg ba~e) with Calcium Carbonate (75 mg) Time Without CaCo3With CaCo3 30.3% 44.0~
36.6% 51.4%
36.9% 53.7%
37.6% 56.8%
40.4% 63.6%
Example 5 Nizatidine with and without calcium carbonate compared at 0 time and l month ~tability (40O; 75%RH), citric acid (1.5%) added to all sample~.
Time Without CaCO3 StabilityWith CaCO3 Stability 30.3 30.0 77.6 45.7 34.8 34.5 82.3 60.3 36.6 37.42 84.2 67.2 38.8 39.4 85.3 70.0 42.9 44.1 94.4 90.3 ~ W 095/05~73 2 PCTrUS94/09204 169 73~
Example 6 Nizatidine granule~ compared in water with tablet with 1.5% citric acid and tablet with 1.5~ of citric acid and 37.5 mg of calcium carbonate.
Time Gran Tab (1.5% C.A.) Tab (C.A. plus CaCO3) O O O O
88.8 39.1 97 Example 7 The proces~ of Example 1 is used with 25% by weight of magnesium al, nllm -~ilicate, 5% of nizatidine, 0.25% of ~od-um ~ac~hAr;n and 1.2%
of citric acid. The granules, before tabletting, were compared with the tabletted product and with the Ch~ --hl e tablet with 5% of calcium carbonate.
Time Gran (Without CaCO,) (With CaCO7) O O O O
37 45 92.2 39.2 47 93 47.4 47.4 95.7
W 095/OSl73 16~ ~35 PCTrUS94/09204 Example 2 % By Weight A B C D
Ingredient~
Nizatidine USP 5 - - -Cimetidine USP - 5 Ranitidine USP - - 5 Famotidine USP - - - 2 Magne~ium Aluminum Silicate NF 25 25 25 10 Calcium Carbonate 5 5 5 5 Sodium Saccharin NF .25 .25 .25 .125 Mannitol NF Q.S. Q.S. Q.S. Q.S.
Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF
Magne~ium Stearate NF 1.5 1.5 1.5 1.5 Flavorq Q.S. Q.S. Q.S. Q.S.
Purified water~
* Remove during proce-~ing Method of Manufacturing 1. Mix drug with magneqium all nllm ~ilicate and qodium qaccharin in a planetary mixer for five minute~.
2. Add water until a uniform granulation occur~.
3. Dry the granule~.
4. Size the granule~ into fine powder.
5. Add mannitol,.xylitol, calcium carbonate, colloidal ~olicon dioxide to and mix for ten minutes.
6. Add magne~ium -qtearate and mix for five minute~.
7. Compre~ into chewable tablet~.
W 095/05173 ~69 PCTrUS~ 204 ~
If the operator wi~he~ an acid agent ~uch a~ a fruit acid, for example, citric, malic or tartaric acid in the formulation, thi~ i~
added to the -n~f~cturing proce~ at Step 1 before the granulation procesR, u~ually at about 1.5%.
The following comparative examples were ~elected to illu~trate the enhanced relea~e of active ingredient from the granule-~/tablet~ of this invention uYing the preparative and te~ting procedure-Q de~cribed above.
Example 3 The percentage of cimetidine di~301ved in water using the U.S.P.
method II at 50 RPM to 60 minute~ from granule~ with added citric acid (3~), calcium carbonate (75 mg) and without calcium carbonate.
Time Without CaCO3 With CaCO3 39.967.5 44.674.4 46.978.8 48.382.8 51.6104.3 Example 4 Ranitidine Hydrochloride (75 mg ba~e) with Calcium Carbonate (75 mg) Time Without CaCo3With CaCo3 30.3% 44.0~
36.6% 51.4%
36.9% 53.7%
37.6% 56.8%
40.4% 63.6%
Example 5 Nizatidine with and without calcium carbonate compared at 0 time and l month ~tability (40O; 75%RH), citric acid (1.5%) added to all sample~.
Time Without CaCO3 StabilityWith CaCO3 Stability 30.3 30.0 77.6 45.7 34.8 34.5 82.3 60.3 36.6 37.42 84.2 67.2 38.8 39.4 85.3 70.0 42.9 44.1 94.4 90.3 ~ W 095/05~73 2 PCTrUS94/09204 169 73~
Example 6 Nizatidine granule~ compared in water with tablet with 1.5% citric acid and tablet with 1.5~ of citric acid and 37.5 mg of calcium carbonate.
Time Gran Tab (1.5% C.A.) Tab (C.A. plus CaCO3) O O O O
88.8 39.1 97 Example 7 The proces~ of Example 1 is used with 25% by weight of magnesium al, nllm -~ilicate, 5% of nizatidine, 0.25% of ~od-um ~ac~hAr;n and 1.2%
of citric acid. The granules, before tabletting, were compared with the tabletted product and with the Ch~ --hl e tablet with 5% of calcium carbonate.
Time Gran (Without CaCO,) (With CaCO7) O O O O
37 45 92.2 39.2 47 93 47.4 47.4 95.7
Claims (11)
1. An oral pharmaceutical dosage unit composition for inducing H2-antagonist activity, which composition is designed for at least partial release of its H2-antagonist ingredient in the mouth, consisting essentially of from 1-35% by weight of said composition of calcium carbonate and of a complex which is prepared from a nontoxic but therapeutically effective quantity of said H2-antagonist ingredient and an excess of aluminum magnesium silicate.
2. The composition of claim 1 in which said complex is prepared during formulation of said composition and the aluminum magnesium silicate is selected from the range of 10-30% by weight of said composition.
3. The composition of claim 2 in which the composition is a chewable tablet.
4. The composition of claim 1 in which famotidine, ranitidine or cimetidine is the drug.
5. The composition of claim 1 in which nizatidine is the drug.
6. The composition of claim 1 in which xylitol or mannitol is present as a bulking -sweetening agent.
7. The composition of claim 2 in which the calcium carbonate is present in from 75 to 500 mg.
8. The composition of claim 2 in which up to 3% by weight of citric, malic or tartaric acid is present.
9. The composition of claim 8 in which 5% by weight of calcium carbonate is present.
10. The composition of claim 9 in which said active ingredient is nizatidine.
11. The composition of claim 9 in which said active ingredient is ranitidine.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10712693A | 1993-08-17 | 1993-08-17 | |
| US08/107,126 | 1993-08-17 | ||
| US28871194A | 1994-08-12 | 1994-08-12 | |
| US08/288,711 | 1994-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2169735A1 true CA2169735A1 (en) | 1995-02-23 |
Family
ID=26804421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2169735 Abandoned CA2169735A1 (en) | 1993-08-17 | 1994-08-16 | Oral compositions of h2-antagonists |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0715516A1 (en) |
| JP (1) | JPH09501680A (en) |
| AU (1) | AU7565594A (en) |
| CA (1) | CA2169735A1 (en) |
| WO (1) | WO1995005173A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622980A (en) * | 1993-08-17 | 1997-04-22 | Applied Analytical Industries, Inc. | Oral compositions of H2-antagonists |
| US6537525B1 (en) * | 1997-01-29 | 2003-03-25 | Douglas H. West | Medicated chewing-gum |
| DE10206089A1 (en) | 2002-02-13 | 2002-08-14 | Zimmer Ag | bursting |
| US20100226979A1 (en) * | 2006-03-21 | 2010-09-09 | Jubilant Organosys Limited | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate |
| CA3079131A1 (en) | 2017-11-09 | 2019-05-16 | 11 Health and Technologies Inc. | Ostomy monitoring system and method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE128351T1 (en) * | 1991-04-04 | 1995-10-15 | Procter & Gamble | EDIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING DIGESTIVE TRACT PAIN. |
| US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
-
1994
- 1994-08-16 CA CA 2169735 patent/CA2169735A1/en not_active Abandoned
- 1994-08-16 WO PCT/US1994/009204 patent/WO1995005173A1/en not_active Application Discontinuation
- 1994-08-16 JP JP7507128A patent/JPH09501680A/en active Pending
- 1994-08-16 EP EP94925883A patent/EP0715516A1/en not_active Withdrawn
- 1994-08-16 AU AU75655/94A patent/AU7565594A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09501680A (en) | 1997-02-18 |
| WO1995005173A1 (en) | 1995-02-23 |
| EP0715516A1 (en) | 1996-06-12 |
| AU7565594A (en) | 1995-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU681672B2 (en) | Preparations containing silicon dioxide to improve the taste thereof | |
| US5225197A (en) | Pharmaceutical formulation | |
| CA2311734C (en) | Flash-melt oral dosage formulation | |
| JP2918691B2 (en) | Ranitidine composition | |
| US20030083354A1 (en) | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions | |
| EP0349103B1 (en) | Chewable tablet | |
| HRP20030527A2 (en) | Pharmaceutical compositions comprising amlodipinemaleate | |
| US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
| US5468504A (en) | Effervescent pharmaceutical compositions | |
| US5622980A (en) | Oral compositions of H2-antagonists | |
| CA2169735A1 (en) | Oral compositions of h2-antagonists | |
| JP3587869B2 (en) | Pharmaceutical composition | |
| WO1996004888A1 (en) | Oral compositions of h2-antagonists | |
| US20040132827A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
| WO1996019220A1 (en) | A combination product comprising nitazoxanide and an anti-ulcer agent | |
| AU654313B2 (en) | Pharmaceutical compositions | |
| SK19192000A3 (en) | Method of treatment | |
| CN1140996A (en) | Ranitidine and calcium carbonate pharmaceutical combination product | |
| EP0574624A1 (en) | Pharmaceutical compositions | |
| CN1146150A (en) | Low dosage ranitidine compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |